Valuation: Novartis AG

Market Cap 285B 250B 230B 216B 404B 26,884B 413B 2,768B 1,071B 13,287B 1,070B 1,047B 46,073B P/E 2026 *
21.6x
P/E 2027 * 18.3x
Enterprise Value 317B 278B 256B 240B 450B 29,924B 459B 3,082B 1,192B 14,789B 1,191B 1,165B 51,283B EV / Sales 2026 *
5.57x
EV / Sales 2027 * 5.19x
Free-Float
91.66%
Yield 2026 *
2.84%
Yield 2027 * 2.93%
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Chief Tech/Sci/R&D Officer 64 2022-05-15
Director TitleAgeSince
Director/Board Member 68 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+7.48%+9.87%+52.28%+167.43% 1,006B
+3.53%+10.05%+67.44%+55.55% 589B
+6.39%+8.54%+33.66%+85.00% 430B
-0.66%+5.11%+29.26%+21.27% 331B
+1.82%+8.19%+41.15%+26.80% 288B
+0.73%+8.53%-26.22%-40.85% 213B
+3.59%+3.73%+28.11%+59.12% 190B
+1.93%+2.63%+19.08%+67.39% 154B
+2.45%-3.67%-0.33%-34.51% 135B
Average +2.49%+4.40%+27.16%+45.24% 370.63B
Weighted average by Cap. +3.66%+4.75%+39.27%+78.14%

Financials

2026 *2027 *
Net sales 56.92B 49.91B 46.01B 43.07B 80.76B 5,370B 82.44B 553B 214B 2,654B 214B 209B 9,202B 60.4B 52.96B 48.82B 45.7B 85.7B 5,698B 87.48B 587B 227B 2,816B 227B 222B 9,765B
Net income 14.16B 12.41B 11.44B 10.71B 20.09B 1,335B 20.5B 138B 53.21B 660B 53.16B 52B 2,289B 15.73B 13.79B 12.71B 11.9B 22.32B 1,484B 22.78B 153B 59.13B 733B 59.07B 57.78B 2,543B
Net Debt 32.23B 28.26B 26.05B 24.38B 45.73B 3,040B 46.67B 313B 121B 1,502B 121B 118B 5,210B 28.74B 25.2B 23.23B 21.75B 40.78B 2,711B 41.63B 279B 108B 1,340B 108B 106B 4,647B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA